Abstract 236P
Background
This study aimed to determine the changes to body composition and the risk of adverse effects associated with chemotherapy in patients with advanced urothelial carcinoma (UC). The study also investigated whether bioimpedance analysis (BIA) is an effective method for diagnosing body composition.
Methods
We prospectively evaluated the body composition of 60 patients with locoregional muscle invasive (≥ T2 and N0-2M0) or metastatic UC between April 2021 and June 2023 at the Department of Urology, Juntendo Nerima Hospital, Tokyo, Japan. Body composition was evaluated using multifrequency BIA at baseline and during chemotherapy. The change in body composition was compared between before and during chemotherapy, and the incidence of adverse events was also determined.
Results
Twelve of the 60 patients enrolled in the study failed to complete their planned chemotherapy regimens or the chemotherapy regimen was discontinued or changed due to adverse events or problems related to underlying cancer. The patients who discontinued their treatment were significantly older and had a low muscle mass and a low skeletal muscle index. To assess the time-course changes in the body composition of the 41 patients who underwent chemotherapy, BIA was performed before each cycle. Chemotherapy-associated changes included a reduction in body weight 1.3% (±0.6%) and a decrease in fat mass 6.4% (±3.4%), while muscle mass did not change 0 .0% (±0.8%) between each cycle. Patients, aged 75 years or younger, had a more significant loss of muscle mass than older patients with a low muscle mass at baseline. (2.3% ± 1.0 % vs -1.4% ±1.1%, p=0.033).
Conclusions
BIA may be used as a method of nutrition and muscle assessment for pretreatment risk stratification of patients with advanced UC treated with chemotherapy. Moreover, our findings suggest that elderly patients with a low muscle mass may have trouble completing their chemotherapy course. Furthermore, chemotherapy is associated with changes in body composition which may lead to a loss of muscle mass in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract